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Abstract
Gastrointestinal stromal tumors (GIST) are thought to derive from the interstitial cells of Cajal (ICC) or an ICC precursor.
Oncogenic mutations of the KIT or PDGFRA receptor tyrosine kinases are present in the majority of GIST, leading to ligand-
independent activation of the intracellular signal transduction pathways. We previously investigated the gene expression
profile in the murine Kit
K641E GIST model and identified Ntsr1 mRNA, encoding the Neurotensin receptor 1, amongst the
upregulated genes. Here we characterized Ntsr1 mRNA and protein expression in the murine Kit
K641E GIST model and in
tissue microarrays of human GIST. Ntsr1 mRNA upregulation in Kit
K641E animals was confirmed by quantitative PCR. Ntsr1
immunoreactivity was not detected in the Kit positive ICC of WT mice, but was present in the Kit positive hyperplasia of
Kit
K641E mice. In the normal human gut, NTSR1 immunoreactivity was detected in myenteric neurons but not in KIT positive
ICC. Two independent tissue microarrays, including a total of 97 GIST, revealed NTSR1 immunoreactivity in all specimens,
including the KIT negative GIST with PDGFRA mutation. NTSR1 immunoreactivity exhibited nuclear, cytoplasmic or mixed
patterns, which might relate to variable levels of NTSR1 activation. As studies using radio-labeled NTSR1 ligand analogues
for whole body tumor imaging and for targeted therapeutic interventions have already been reported, this study opens
new perspectives for similar approaches in GIST.
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Introduction
Gastrointestinal stromal tumors (GIST) are the most common
sarcoma of the gastrointestinal tract. They are thought to derive from
the interstitialcells ofCajal (ICC) or an ICC precursor. Approximately
85% of GIST harbor oncogenic KIT mutations and 7% contain
oncogenic platelet-derived growth factor receptor alpha (PDGFRA)
mutations. KIT and PDGFRA are members of the type III receptor
tyrosine kinase family. Oncogenic mutation of KIT or PDGFRA lead
to constitutive autophosphorylation, ligand-independent activation of
the downstream signal transduction pathways and subsequent
deregulation of cell proliferation, survival and migration [1,2].
Since the release of imatinib mesylate (a.k.a. STI571, Gleevec
TM),
an inhibitor of KIT and PDGFRA activation, the immunohisto-
chemical demonstration of KIT immunoreactivity (-ir) has been
essentialforthediagnosisofGIST[3].However,upto15%ofGIST
show weak or negative staining for KIT [4]. Many of these
‘‘KIT-negative’’ GISTharbor PDGFRA mutationsand may respond
to imatinib treatment [5,6], hence need to be classified correctly.
Recently, Discovered on GIST-1 (DOG1, a.k.a anoctamin, ANO1),
Protein kinase C theta (PKC theta) and Carbonic anhydrase II
(CAII) have been suggested as additional diagnostic markers and/or
putative therapeutictargets [7–10]. Noteworthy, thesegenesare also
expressed in normal KIT-ir ICC [7,10,11] and belong to the gene
expression profile of KIT-ir ICC in the mouse small intestine [12].
Their presence in GIST thus likely reflects the fact that these tumors
arise from the lineage of KIT-ir ICC.
We have recently identified genes expressed in GIST, but not in
normal KIT-ir ICC, by comparing gene expression profiles of the
antrum of transgenic mice harboring the oncogenic Kit K641E
mutation [13] and WT littermates, using cDNA microarray. The
G-protein-coupled receptor (GPCR), Neurotensin receptor 1 (Ntsr1)
appeared highly upregulated in Kit
K641E antrum [14], while it did
notbelong tothegene expressionprofile ofnormalKit-irICCinthe
mouse small intestine [12]. As studies using radio-labeled NTSR1
ligand analogues have already been reported for whole body tumor
imagingand fortherapeuticinterventions[15],NTSR1appeared as
an interesting prospect. Hence we have characterized Ntsr1
expression in the murine Kit
K641E GIST model, in the normal
human gut wall and inhumanGIST. NTSR1-ir was notdetected in
normal KIT-ir ICC, but was present in all GIST investigated,
including KIT negative GIST harboring PDGFRA mutations.
Materials and Methods
The Kit
K641E murine model of GIST
A knock-in Kit
K641E murine model of GIST used in this study has
beenpreviouslydescribed[13].Twoweeksold(P14)Kit
K641E/K641E,
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WT/K641E and Kit
WT/WT littermates, as well as adult (3–6 month
old) Kit
WT/K641E and Kit
WT/WT animals, were used. Mice were bred
and experiments performed in accordance with the ethics
committee for animal well-being of the Faculty of Medicine,
Universite ´ Libre de Bruxelles, Brussels, Belgium.
RNA Extraction and PCR. Total RNA was extracted from
mouse antrum using RNeasy Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions as described [14].
Genomic DNA was removed with the DNA-free
TM kit (Ambion,
Inc., Austin, Texas). RNA (1 mg) was reverse transcribed with
200 units of M-MLV Reverse Transcriptase (Invitrogen, Eugene,
Oregon) in a reaction containing random primers (Amersham
Bioscience, Piscataway, NJ). For reverse transcription PCR (RT-
PCR) the cDNA reverse transcription product was amplified
with specific primers (Table 1) using 1U Taq DNA polymerase
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions, during 40 cycles of 94uC for 30 sec, 57uCf o r
45 sec and 72uC for 45 sec. PCR products were separated on
2% agarose gel, stained with ethidium bromide and
photographed under UV illumination. Real time quantitative
PCR (qPCR) was performed as described [14], using SYBR
Green chemistry on a 7500 Real time PCR system (Applied
Biosystems, Foster City, CA). Identical conditions, namely 95uC
for 10 min; then 40 cycles of 95uC for 15 sec and 60uCf o r
1 min were used for all primer sets (Table 1). Transcriptional
quantification relative to Gapdh and b-actin housekeeping genes
was performed using Qbase
TM software [16]. Data were
reported as the mean of three independent experiments and
presented as normalized relative quantities (NRQ). Statistical
analysis was performed in Microsoft Office Excel
TM 2003 using
unpaired Student’s t-test. Differences were regarded as
statistically significant when p#0.05.
Immunofluorescence staining (IF). Specimens were
processed as described [14]. Briefly, slides were brought to RT,
rinsed in 10mM Tris (Merck-Belgolabo, Overijse, Belgium) and
0.15M sodium chloride, pH 7.4 TBS, containing 0.1% (v/v)
Triton-X 100 (TBS-TX), and incubated for 1 hour in 10% normal
horse serum (NHS) (Hormonologie Laboratoire, Marloie,
Belgium) and TBS-TX to reduce background staining. The
slides were incubated overnight at RT with the primary antibodies
Table 1. List of primers.
Primers for RT-PCR (human sequence)
NM_006183.3 NT/N F 59-AGGGCTTTTCAACACTGGGAG- 39
NT/N R 59-TCATACACGTGCCGTTTCAGA- 39
NM_002531.2 NTSR1 R 59-GTTGATGGTGGAGCTGACGTAG- 39
NTSR1 F 59-GGATGAGCAGTGGACTCCGT- 39
NM_001101.3 b-ACTIN F 59-CATCCACGAAACTACCTTCAACTCC- 39
b-ACTIN R 59-GAGCCGCCGATCCACAC- 39
Primers for q-PCR (murine sequence)
NM_018766.2 Ntsr1 F 59-CAAGGTCGTCATCCAGGTTAACAC- 39
Ntsr1 R 59-CCATGACGGTCAGTTTGTTGG- 39
NM_008747.2 Ntrs2 F 59-CTCAGAGCCATCGTGGCTGT- 39
Ntsr2 R 59-GAAGACACGGCGTTGTAGAGGA- 39
NM_019972.2 Ntsr3 F 59-GAGACAAATGCCAAGGTGGG- 39
Ntsr3 R 59-ACTTGGAATTCTGCTTTGTGGG- 39
NM_008084.2 Gapdh F 59-TGTGTCCGTCGTGGATCTGA- 39
Gapdh R 59-CCTGCTTCACCACCTTCTTGA- 39
NM_007393.3 b-actin F 59-AACCGTGAAAAGATGACCCAGAT- 39
b-actin R 59-GCCTGGATGGCTACGTACATG- 39
doi:10.1371/journal.pone.0014710.t001
Table 2. Clinicopathologic features of the Cleveland Clinic
GIST TMA.
Primary tumor site Total (n)
Gastric 34
Small bowel 9
Colon 2
Rectovaginal 1
Disseminated 3
Tumor morphology Total (n)
Spindle 35
Epithelioid 14
Risk category Total (n)
Malignant 7
High risk 10
Moderate risk 13
Low risk 8
Very low risk 6
No risk 5
Mitotic Figures Total (n)
#5/50 HPF 26
.5/50 HPF 17
N.A. 6
Mutation Status Total (n)
KIT mutation 25
KIT Exon 9 AY 502-503 duplication 4
KIT Exon 11 duplication 3
KIT Exon 11 deletion 6
KIT Exon 11 deletion - MYEV 552–555 1
KIT Exon 11 deletion - PMYE 551–555 1
KIT exon 11 V559D 6
KIT exon 11 V560D 1
KIT Exon 11 V600D 1
KIT exon 11 W557G 1
KIT Exon 13 K642E 1
PDGF mutation 9
PDGFRA Exon 12 - V561D 2
PDGFRA exon 12 deletion 1
PDGFRA Exon 18 D842V 4
PDGFRA Exon 18 D842Y 1
PDGFRA Exon 18 Ins-Del 1
Wild type 11
N.A. 4
KIT-ir Total (n)
positive 44
negative 4
N.A. 1
Footnote: N.A.: data not available
doi:10.1371/journal.pone.0014710.t002
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Cruz Biotechnology, Inc., Santa Cruz, Ca), rinsed twice in TBS
and incubated in the dark for 1 hour at RT in TBS containing the
secondary antibodies anti rabbit biotinylated; 1:200 (Jackson
Immunoresearch, Cambridge, UK) and anti goat Alexa
TM 448
conjugated; 1:200 (Invitrogen, Eugene, Oregon). Slides were then
rinsed twice in TBS and incubated in the dark for 1 hour at RT
with streptavidin-coupled NorthernLight
TM 557 (NL557) (R&D
Systems, Abingdon, Oxon, UK) in TBS. Secondary antibodies
anti rabbit DyLight
TM 549 conjugated; 1:200 (Jackson
Immunoresearch, Cambridge, UK) were used for GIST882 cells
immunolabeling.
The optimal working dilution was determined empirically for
each antibody. The protocol used for double immunofluorescence
staining did not modify the distribution or the intensity of each
individual labeling observed in corresponding single procedures.
Omission of the primary or of the secondary antibodies resulted in
the absence of the respective fluorescent signal.
Nuclei were stained with 5 mM Hoechst in Tris-HCl (Merck-
Belgolabo, Overijse, Belgium) 0.05M (pH 7.4), containing
0.5 mg/ml type 1-AS Ribonuclease A for 5 min in the dark at RT.
After three rinses in TBS, preparations were mounted with
Fluor Save
TM Reagent anti-fade mounting medium (Calbiochem,
Nottingham, UK).
Confocal microscopy. Preparations were viewed under a
LSM510 NLO multiphoton confocal microscope fitted on an
Axiovert M200 inverted microscope equipped with a C-
Apochromat 406/1.2 N.A. water immersion objective (Zeiss,
Iena, Germany).
The 543 nm excitation wavelength of the HeNe1 laser, a main
dichroic HFT 488/543/633 and a long-pass emission filter (LP560
nm) were used for selective detection of the red fluorochrome. The
nuclear stain Hoechst was excited in multiphotonic mode at
760 nm with a Mai Tai
TM tunable broad-band laser (Spectra-
Physics, Darmstad, Germany) and detected using a main dichroic
HFT KP650 and a band-pass emission filter (BP435–485 nm).
Single optical sections, 2 mm thick, were collected for each
fluorochrome sequentially. The images generated (pixel size:
0.1 mm) were merged and analyzed with the Zeiss LSM510
software and exported in .jpg image format.
Epifluorescence microscopy. Slides were examined under
an AxioImager Z1 (Zeiss, Oberkochen, Germany) equipped with a
Plan-Neofluar 406/0.75 N.A. dry objective and band-pass filter
sets nr 38, 15 and 49 for green, red and blue fluorochromes,
respectively, using AxioVision software (Zeiss, Oberkochen,
Germany).
Human GIST tissue micro array (TMA)
We examined NTSR1-ir in 2 independent cohorts of GIST
using tissue microarray slides of formalin-fixed, paraffin-embedded
(FFPE) material. As the clinico-pathological characteristics avail-
able for the two cohorts had not been recorded in a uniform way,
they were analyzed separately.
For the Cleveland Clinic GIST TMA, a cohort of human
GIST samples was retrieved from the anatomic pathology files of
the Cleveland Clinic. The collection and analysis of human
tissue samples was approved by the Cleveland Clinic Institu-
tional Review Board. GIST samples were used to construct a
tissue microarray with 1 mm cores using a TMarrayer
TM (P/N
02110016) semi-automated tissue arrayer (Pathology Devices,
Westminster, MD, USA) Risk assessment was performed using
the criteria of Miettinen and Lasota [17] as recommended by
the National Cancer Care Network [18]. Mutations in KIT
exons 9, 11, 13, and 17 and PDGFRA exons 12 and 18 were
examined as described previously [5]. Each case was present in
duplicate on in this array. Clinico-pathological characterization
of GIST used for Cleveland Clinic GIST TMA is summarized in
Table 2.
SuperBiochips GIST TMA was purchased from Super
BioChips laboratories, (#ADD1 , Seoul, South Korea). It
contained 48 formalin-fixed and paraffin-embedded human
GIST tissue specimens and 9 matched normal gut tissue
specimens. According to the manufacturer, specimens (2 mm
cores) were prepared from surgical specimens of American
patients with GIST under guarantee in US law. Risk assessment
was performed according to Fletcher et al. [3]. The clinico-
pathological characterization of this GIST cohort is summarized
in Table 3.
Immunohistochemistry (IHC) on FFPE human
material. After rehydration through phenol and graded
alcohols, TMA slides were heated at 96uC in 10mM Citrate
buffer (pH 6.0) for 20 min to achieve epitope unmasking. Slides
were then cooled for 30 min then rinsed in TBS. The staining
with primary NTSR1 (C-20); 1:50 (Santa Cruz Biotechnology,
Inc., Santa Cruz, Ca), Kit/CD117; 1:500 (Dako North America,
Inc., Carpinteria, CA) antibodies and secondary anti-rabbit or
anti-goat biotinylated antibodies; 1:200 (Jackson Immu-
noresearch, Cambridge, UK), respectively, was performed as
mentioned above for IF. Then sections were incubated in ABC
solution (ABC kit standard PK-4000; Vector Laboratories,
Burlingame, CA) for 90 min at room temperature and
peroxidase activity revealed for 5–10 min with nickel-enhanced
DAB (DAB-Ni), resulting in a black precipitate. The DAB-Ni
solution was prepared by dissolving 0.3 g of nickel ammonium
sulfate (Fluka, Buchs, Switzerland) and 10 mg of DAB (Sigma, St.
Louis, MO) in 50 ml of 0.05 M Tris/HCl, pH 7.6. Immediately
Table 3. Clinicopathologic features of the SuperBiochips GIST
TMA.
Sex/Age average Total (n)/years
Male 28/58.3
Female 20/62.6
Primary tumor site Total (n)
Gastric 22
Small bowel 15
Abdominal cavity 1
Rectum 2
Disseminated 8
Risk category Total (n)
Malignant 8
High risk 24
Intermediate risk 8
Low risk 8
Mitotic Figures Total (n)
#5/50 22
.5/50 26
KIT-ir Total (n)
positive 48
negative 0
doi:10.1371/journal.pone.0014710.t003
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Staining was regarded as positive when specific (i.e. above
background) NTSR1-ir signal was present in $10% of tumor cells.
The pattern of subcellular distribution of NTSR1-ir was recorded
as: nuclear (without distinct cytoplasmic staining), cytoplasmic
(without distinct nuclear staining), or mixed. x
2 (chi-squared),
Fisher’s exact test and Student’s t-test, were used to test possible
association between Ntsr1-ir and the clinico-pathological features
of the tumors.
Human GIST882 cell line
The human GIST cell line GIST882 [19] was kindly provided
by Dr. Jonathan A. Fletcher, Harvard Medical School, Boston,
Massachusetts, USA. Cells were cultured at 37uC in DMEM
(GIBCO, California USA) supplemented with 10% fetal bovine
serum (FBS), 2% Penicillin/Streptomycin. Cells were starved
overnight in minimal medium (i.e. without FBS), before
stimulation with the NTSR1 agonist JMV449 (10 mM) (Tocris
Bioscience, Ellisville, MO) for 4 hours.
Western blotting (WB). Cells were lysed in buffer containing
10 mM Tris-HCl (pH 7.5), 150 mM KCl, 100M NaF, 0.5%
Nonidet P-40, 12mM B-mercaptoethanol and 20 ml/ml proteases
inhibitor mixture (Roche; Mannheim, Germany). Proteins were
solubilized in sample buffer, heated at 95uC for 5 min, separated
by SDS-PAGE on 8% polyacrylamide gel and transferred on a
0.2 mm nitrocellulose membrane. Primary anti-NTSR1 antibody
(C-20); 1:100 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
secondary anti-goat IgG DyLight800 antibody; 1:10000 (Pierce,
Thermo Fisher Scientific, Erembodegem, Belgium) and the
Odyssey
TM imaging system (LI-COR Biotechnology, Lincoln,
NE) was used to reveal the signal.
Results
Ntsr1 expression in murine Kit
K641E GIST model
Ntsr1 mRNA expression is up-regulated in KitK641E
antrum. Relative expression of Ntsr1 mRNA was markedly
increased in Kit
K641E/K641E homozygous P14 antrum compared to
Kit
WT/WT littermates (NRQ=48.7; p=7.7e-6) while Ntsr1
Figure 1. Ntsr1-ir is expressed in the hyperplastic layer of Kit-ir cells in Kit
K641E antrum but not in WT ICC. A: In P14 antrum, Ntsr1
mRNA exhibited significant upregulation in Kit
K641E/K641E homozygous compared to Kit
WT/WT littermates. Ntsr1 expression in heterozygous Kit
WT/K641E
animals did not differ significantly from their Kit
WT/WT littermates. Three animals of each genotype were used for quantification. Data are reported as
the mean6SEM and presented as normalized relative quantities (NRQ), (**) p,0.005. B: In adult antrum, expression of Ntsr1 mRNA was moderately
increased in Kit
WT/K64iE heterozygous compared to Kit
WT/WT littermates. Three animals of each genotype were used for quantification. Data are
reported as the mean6SEM and presented as normalized relative quantities (NRQ), (*) p,0.05. C: Representative single confocal images of Ntsr1-ir
distribution in the P14 mouse antrum: Ntsr1-ir (NL559, red) was observed in the Kit-ir (Alexa 488, green) hyperplastic layer of P14 homozygous
Kit
K641E/K641E antrum (lower row) but was not present in the Kit-ir ICC in WT littermates (upper row). Ntsr1-ir was also consistently found in the
myenteric plexus (white arrows) and intramuscular nerve fibers in all genotypes. Scale bar: 20 microns. Fluorescence intensity plots along the yellow
lines illustrate the respective distribution of Ntsr1-ir (NL559, red) and Kit-ir (Alexa 488, green).
doi:10.1371/journal.pone.0014710.g001
NTSR1 in GIST but Not in ICC
PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e14710expression in heterozygous Kit
WT/K641E P14 animals was similar
to their WT Kit
WT/WT littermates (Fig. 1A). Kit
K641E/K641E
homozygous animals usually die before weaning. In the
antrum of adult mice, the relative increase of Ntsr1 ex-
pression in Kit
WT/K641E heterozygous compared to Kit
WT/WT
littermates was moderate, but significant (NRQ=2.9; p=0.049)
(Fig. 1B).
Ntsr2 transcript was detected neither in Kit
K641E/K641E homo-
zygous P14 antrum nor in Kit
WT/WT littermates. Relative Ntsr3
mRNA expression did not differ in Kit
K641E/K641E homozygous
P14 antrum compared to Kit
WT/WT littermates (p=0.33) (data not
shown).
Ntsr1-ir is not present in WT ICC. Ntsr1-ir was observed
in the myenteric plexus and intramuscular nerve fibers in P14
Kit
WT/WT (Fig. 1C upper row), as well as in adult Kit
WT/WT
animals (Fig. S1). Conversely, ICC, identified by Kit-ir, were
consistently negative for Ntsr1-ir in WT animals.
Ntsr1-ir is expressed in the hyperplastic layer of Kit-ir
cells in KitK641E antrum. In the antrum of P14 Kit
K641E/K641E
animals, Ntsr1-ir decorated the Kit-ir hyperplastic layer (Fig. 1C
bottom row), while in P14 Kit
WT/K641E heterozygous antrum,
Ntrs1-ir did not differ from P14 WT animals (data not shown).
In adult heterozygous Kit
WT/K641E animals, Ntsr1-ir was detected
also in hyperplastic clusters of Kit-ir cells but not in individual
Kit-ir ICC without sign of hyperplasia (Fig. S1). In all genotypes,
myenteric plexus and intramuscular nerve fibers consistently
exhibited Ntsr1-ir.
NTSR1 expression in human GIST
NTSR1-ir is not present in human KIT-ir ICC. In the
normal human colon, NTSR1-ir was detected in MP but not in
the adjacent KIT-ir ICC (Fig. 2 upper row). Omission of primary
antibody completely wiped out the signal and background (non-
specific) signal in other cell types was minimal.
In a human GIST with KIT K642E mutation, NTSR1-ir was
present only in the KIT-ir tumor cells (Fig. 2 bottom row).
NTSR1-ir is present in human GIST irrespective to the
mutation status. Immunohistochemistry for NTSR1 was
performed on two independent TMA including a total of 97
GIST. 95 samples were considered for analysis, 2 spots were
excluded due to poor quality of tissue. Clinico-pathological
characteristics of the GIST cases are summarized in Tables 2 and 3.
All GIST stained positively for NTSR1-ir (Fig. 3A left and
Fig. 3B). In adjacent non-tumoral tissue, NTSR1-ir was present in
myenteric plexus but not in other cell types (Fig. 3A middle and
right, respectively). Background (non specific) signal in non-
tumoral tissue was minimal, confirming the specificity of the
NTSR1-ir signal observed on TMA.
Noteworthy, 4 KIT negative GIST with PDGFRA mutation
were positive for NTSR1 staining (Fig. 3B). All 4 cases were of
gastric origin, 3/4 showed epithelioid morphology and belong to
the low-moderate risk category (Table 4).
Three patterns of NTSR1-ir were observed (Fig. 4): nuclear,
without distinct cytoplasmic staining (Fig. 4A); cytoplasmic, without
distinct nuclear staining (Fig. 4B); and mixed staining pattern, with
NTSR1-ir present in nucleus as well as in cytoplasm (Fig. 4C).
Mixed and nuclear staining were occasionally encountered in close
vicinity (Fig. 4D) and were regarded as mixed patterns. A majority
of GIST (63/95) showed mixed (nuclear + cytoplasmic) NTSR1-ir.
The pattern of NTSR1-ir was exclusively cytoplasmic in 25/95
samples and exclusively nuclear in 7/95 (Tables 5 and 6).
Altogether, no statistically significant correlation could be found
between NTSR1-ir and the GIST clinico-pathological features.
NTSR1 - but not Neurotensin (NT) - is expressed in the
human GIST882 cell line
In the human GIST882 cell line, NTSR1 expression was
confirmed by RT-PCR (Fig. S2A). and WB (Fig. S2B) while
Figure 2. NTSR1-ir is present in a human GIST with KIT K642E mutation but not in normal human KIT-ir ICC. Representative
epifluorescence microscopy images of NTSR1-ir distribution in the human gut: In the normal human colon, NTSR1-ir (NL559, red) was detected in
myenteric plexus (white arrows) but not in the adjacent KIT-ir (Alexa 488, green) ICC (upper row). In a human GIST with KIT K642E mutation, NTSR1-ir
colocalized with KIT-ir in the tumor cells (lower row). Scale bar: 20 microns. Fluorescence intensity plots along the yellow lines illustrate the respective
distribution of NTSR1-ir (NL559, red) and KIT-ir (Alexa 488, green).
doi:10.1371/journal.pone.0014710.g002
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not detected by RT-PCR. The human astrocytoma cell line
1321N1 served as positive control (Fig. S2A).
NTSR1-ir translocates to the nucleus upon agonist
stimulation in GIST882 cells. After overnight starvation in
FBS free medium (to avoid any NT that might be present in FBS),
GIST882 cells exhibited diffuse perinuclear cytoplasmic, as well as
nuclear, NTSR1-ir. Application of the NTSR1 agonist JMV449
(10 mM) for 4 hours markedly enhanced nuclear NTSR1-ir and
redistributed cytoplasmic NTSR1-ir into dot-like clumps (Fig. S2C).
Discussion
To the best of our knowledge, the distribution of NTSR1-ir in
the muscularis propria of the gut had not been previously
reported. We observed NTSR1-ir in the soma of myenteric
Figure 3. NTSR1-ir in human GIST is irrespective to the mutation status. NTSR1 and KIT immunohistochemistry on FFPE human TMA.
A: Representative example of NTSR1-ir in a gastric GIST (left). NTSR1-ir was also present in adjacent myenteric plexus (arrows) (middle) while adjacent
non tumoral tissue (*) (right) exhibited only minimal background (non specific) signal. B: Column 1 and 2: Representative examples of NTSR1-ir in KIT-
ir GIST while (KIT negative) non-tumoral tissue exhibited only minimal (non specific) background signal. Column 3: Example of a KIT negative GIST
with PDGFRA mutation positive for NTSR1-ir. Scale bars in A and B: 20 microns.
doi:10.1371/journal.pone.0014710.g003
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and human gut, while the KIT-ir ICC and other cell types were
not labeled.
Conversely, NTSR1-ir was consistently detected in the
hyperplastic Kit-ir cells in the murine Kit
K641E GIST model and
in all 95 human GIST investigated, irrespective of the presence of
KIT-ir or KIT/PDGFRA mutation. The expression of NTSR1-ir
in GIST, but not in normal ICC, contrasts with other markers
recently reported in human GIST, which are generally also
expressed in normal ICC [7,10,11].
We have identified three distinctive patterns of NTSR1-ir
(nuclear; cytoplasmic; mixed) in GIST TMA but they could not
be correlated with the recorded histopathological characteristic of
the tumors. Nuclear localization of NTSR1 has been linked to cell
responses evoked by intense and persistent agonist stimuli. [20–23].
NT, the natural NTSR1 high-affinity ligand, is a gut hormone
normally present in serum and surges upon feeding [24,25]. In
tissues, NTcanalsobe produced by tumoral cells[26]orbyreactive
cells in their vicinity [22,27–30], creating autocrine or paracrine
activating loops, respectively. Hence, the variable proportions of
Table 4. Clinicopathologic characteristics of NTSR1 positive/KIT negative GIST specimens.
No Morphology Primary site Risk Assessment Mutation Status Size Mitotic Figures NTSR1 -ir
1 Epithelioid gastric moderate PDGFRA Exon 12 13 cm 4/50 HPH mix
2 Epithelioid gastric low PDGFRA Exon 18 5.2 cm 2/50 HPH mix
3 Epithelioid gastric moderate PDGFRA Exon 12 15 cm 1/50 HPH nuclear
4 Spindle gastric moderate PDGFRA Exon 18 17 cm 2/50 HPH nuclear
doi:10.1371/journal.pone.0014710.t004
Figure 4. NTSR1-ir patterns in human GIST. Representative images of NTSR1-ir staining patterns encountered on GIST TMA: A: Nuclear staining.
B: Cytoplasmic staining. C Mixed pattern: NTSR1-ir present in both nucleus and cytoplasm of the tumor cells. D: Mixed pattern: nuclear and
cytoplasmic NTSR1-ir patterns coexisting in adjacent parts of the tumor. Scale bar: 20 microns.
doi:10.1371/journal.pone.0014710.g004
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possibly represents different levels of NTSR1 activation caused by a
complex and dynamic interplay of various sources of ligand and
possibly other factors. The precise origin of NTSR1 activation in
individual GIST remains to be established. In the GIST882 cell
line, the redistribution of NTSR1-ir upon stimulation by the specific
NTSR1 agonist JMV499 suggests the presence of functionally
responsive NTSR1 while the absence of NT/N precursor mRNA
expression rule out an autocrine activation loop in that cell line.
High affinity NTbinding siteshave beenfoundinvariouscancers,
including Ewing’s sarcoma [31] and NTSR1 expression, driven by
the Wnt/b-catenin pathway, is an early event in oncogenic
transformation [22,23]. Sustained activation of NTSR1 leads to
persistent activation of signaling pathways, including ERK1/2 [20],
hence facilitating tumor growth and progression. NTSR1 has been
associated with progression in lung, colon, pancreas, prostate and
breast epithelial cancers [29,30,32]. According to the Gene
Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.
gov/geo/), NTSR1 is also expressed in a variety of sarcoma.
Therefore, NTSR1 expression appears to be linked to tumorigenesis
in general and cannot be used as a diagnostic tool to distinguish
GIST from other tumor types or to predict their risk of malignancy.
Nevertheless, the identification of NTSR1 expression in GIST
but not in the KIT expressing ICC cells from which they derive,
offers clinical perspectives that deserve further consideration.
Firstly, NTSR1 can be targeted with radio-labeled NT analogues
for whole body tumor imaging and possibly even for subsequent
therapeutic interventions. Currently, 18F-Fluoro-deoxyglucose
(18F-FDG) positron emission tomography (PET) is used for
assessing tumor response to tyrosine kinase inhibitors in vivo [33–
35]. However, 18F-FDG-PET cannot differentiate between GIST
and other gastrointestinal malignancies including epithelial cancers
and lymphoma and in some cases, 18F-FDG-PET fails to detect the
relapse of GIST at an early time point [36]. An analogue based on
NT (8–13) NT-XIX, has already been synthesized and character-
ized. Radioactivity clearance of NT-XIX analogue from healthy
organswas fasterthan from tumors,resultinginimproved tumor-to-
tissue ratios and good SPECT/CT imaging [15]. NTSR1 in vivo
imaging has already been successfully used in patients with ductal
pancreatic adenocarcinoma [37]. Therefore NTSR1 in vivo
imaging deserves full consideration in GIST.
NTSR1 may also be considered as a prospective direct
therapeutic target. NT antagonists, such as SR48692.21, coun-
teract the stimulatory effect of NT on tumor cells [22]. The
influence of SR48692.21 on GIST proliferative characteristics thus
deserves consideration.
Finally, NTSR1 could represent the gateway to introduce
cytotoxic chemicals or expression vectors targeting the constitu-
tively activated pathways into the cancerous cells [38–40].
Table 5. NTSR1-ir on the Cleveland Clinic GIST TMA.
Clinicopathologic features NTSR1-ir (n/total)
Nuclear Cytoplasmic Mix
Primary tumor site
Gastric 2/34 7/34 24/34
Small bowel 1/9 1/9 6/9
Colon 1/2 0/2 1/2
Rectovaginal 0/1 1/1 0/1
Disseminated 0/3 1/3 2/3
Tumor morphology
Spindle 4/35 7/35 22/35
Epithelioid 0/14 3/14 11/14
Risk category
Malignant - High 2/17 4/17 11/17
Moderate - Low 2/21 5/21 14/21
Very low - None 0/11 1/11 8/11
Mitotic Figures
#5/50 3/26 2/26 10/26
.5/50 1/17 7/17 18/17
Mutation Status
KIT mutation 3/25 7/25 15/25
KIT Exon 9 AY 502-503 duplication 2/4 0/4 2/4
KIT Exon 11 duplication 0/3 0/3 2/3
KIT Exon 11 deletion 1/6 3/6 2/6
KIT Exon 11 deletion - MYEV 552–555 0/1 0/1 1/1
KIT Exon 11 deletion - PMYE 551–555 0/1 1/1 0/1
KIT exon 11 V559D 0/6 2/6 4/6
KIT exon 11 V560D 0/1 0/1 1/1
KIT Exon 11 V600D 0/1 0/1 1/1
KIT exon 11 W557G 0/1 0/1 1/1
KIT Exon 13 K642E 0/1 1/1 1/1
PDGF mutation 0/9 3/9 6/9
PDGFRA Exon 12 - V561D 0/2 1/2 1/2
PDGFRA exon 12 deletion 0/1 0/1 1/1
PDGFRA Exon 18 D842V 0/4 2/4 2/4
PDGFRA Exon 18 D842Y 0/1 0/1 1/1
PDGFRA Exon 18 Ins-Del 0/1 0/1 1/1
Wild type 1/11 0/11 10/11
doi:10.1371/journal.pone.0014710.t005
Table 6. NTSR1-ir on the SuperBiochips GIST TMA.
Clinicopathologic features NTSR1-ir (n/total)
Nuclear Cytoplasmic Mix
Sex
Male 2/28 8/28 18/28
Female 1/20 7/20 12/20
Primary tumor site
Gastric 2/22 7/22 13/22
Small bowel 0/15 5/15 10/15
Abdominal cavity 0/1 0/1 1/1
Rectum 1/2 1/2 0/2
Disseminated 0/8 2/8 6/8
Risk category
Malignant 0/8 2/8 6/8
High risk 2/24 8/24 14/24
Intermediate risk 1/8 1/8 6/8
Low risk 0/8 4/8 4/8
Mitotic Figures
#5/50 0/22 8/22 14/22
.5/50 3/26 7/26 16/26
doi:10.1371/journal.pone.0014710.t006
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Supporting Information
Figure S1 Ntsr1-ir is expressed in Kit-ir cell clusters in the
antrum of adult heterozygous KitWT/K641E mice but not in WT
ICC. Representative epifluorescence images of Ntsr1-ir distribu-
tion in the adult mouse antrum: Ntsr1-ir (NL559, red) was
observed in Kit-ir (Alexa 488, green) cell clusters (insert) in adult
heterozygous KitWT/K641E mice, but not in WT littermates.
Ntsr1-ir was also consistently found in the myenteric plexus (*) and
intramuscular nerve fibers both genotypes. Scale bars: 20 microns.
Found at: doi:10.1371/journal.pone.0014710.s001 (4.35 MB TIF)
Figure S2 NTSR1 is expressed in the human GIST882 cell line
and responds to agonist stimulation. A: NTSR1 - but not
neurotensin/neuromedin N precursor (NT/N) mRNA - is
expressed in GIST882 cells. Lane 1: GIST882 cDNA, lane 2:
1321N1 cDNA, lane 3: negative control (no template). RT-PCR
revealed the presence of NTSR1 amplicon (90bp) but not NT/N
(121bp) in GIST882 cells while 1321N1 express both NTSR1 and
NT/N. b-ACTIN (213bp) was used as control. B: WB for NTSR1
in GIST882 cells. A single band of the expected MW (54kDa) was
detected. C: Representative confocal microscopy images of
NTSR1-ir patterns in GIST882 cells. Upper row: After overnight
incubation in FBS free medium, a diffused cytoplasmic and
nuclear NTSR1-ir (DyLight 549, red) was observed. Lower row:
After stimulation with the NTSR1 agonist JMV449 for 4 hours,
NTSR1-ir strongly increased in the nucleus and in many cells,
cytoplasmic NTSR1-ir exhibited a dot-like pattern. Scale bar: 20
microns. Fluorescence intensity plots along the yellow lines
illustrate the respective distribution of NTSR1-ir (DyLight 549,
red) and DNA (Hoechst, blue).
Found at: doi:10.1371/journal.pone.0014710.s002 (9.69 MB TIF)
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